A development stage pharmaceutical company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases.


Updates from The Motley Fool

Latest updates on Galectin Therapeutics from Fool.com.


Stock Performance

View Interactive GALT Charts
Sponsored by

Key Data Points

Primary metrics and data points about Galectin Therapeutics.
Current Price: $1.74
Prev Close: $1.94
Open: $1.84
Bid: $1.82
Ask: $1.84
Day's Range: $1.63 - $2.21
52wk Range: $0.49 - $3.05
Volume: 1,580,184
Avg Vol 608,841
Market Cap: $42M
P/E (ttm): -2.34
EPS (ttm): ($0.83)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Galectin Therapeutics.
CAPS Rating 2 out of 5
 
62 Outperform
41 Underperform
CAPS All Stars
 
11 Outperform
26 Underperform

How do you think Galectin Therapeutics will perform against the market?



You pick for Galectin Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Theodore D. Zucconi, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Galectin Therapeutics.

A development stage pharmaceutical company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers